Healthcare Journal of Oregon: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal of Oregon.

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

April 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Press releases published on April 17, 2026

Apr. 17, 2026

Brazilian Wood Claims Evaluated: Discover the Male Enhancement Hardening Pill Truth by SuperNatural Man

GlobeNewswire

Apr. 17, 2026

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

GlobeNewswire

Apr. 17, 2026

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

GlobeNewswire

Apr. 17, 2026

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

GlobeNewswire

Apr. 17, 2026

Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026

GlobeNewswire

Apr. 17, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

GlobeNewswire

Apr. 17, 2026

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

GlobeNewswire

$MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer$

Apr. 17, 2026

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

GlobeNewswire

Apr. 17, 2026

JimStoppani.com Announces Summer Shred Challenge with $25,000 Grand Prize

GlobeNewswire

Apr. 17, 2026

Opticore Eye Group Unveils New Contact Lens Program in Riverside, CA for 2026

GlobeNewswire

Apr. 17, 2026

Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity

GlobeNewswire

Apr. 17, 2026

JellyLean Claims Evaluated: Discover the Untold Truth About Jelly Lean Gelatin Trick Gummies Recipe for Weight Loss

GlobeNewswire

Apr. 17, 2026

Pacemakers Market to Reach $7.5 Billion by 2030, Driven by Expanding Clinical Indications and Aging Demographics

GlobeNewswire

Apr. 17, 2026

Yuhua Zhang, PhD, Named Chairholder of the Carolyn and Chuck Miller Endowed Chair for Vision Research

GlobeNewswire

Apr. 17, 2026

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

GlobeNewswire

Apr. 17, 2026

Global Widget Celebrates 10 Years as a Leader in Premium Gummy Manufacturing

GlobeNewswire

Apr. 17, 2026

Omada Health Helps Members on GLP‑1s Lose More Fat, Preserve Muscle Mass, and Improve Mental Health, New Study Finds

GlobeNewswire

Apr. 17, 2026

Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight

GlobeNewswire

Apr. 17, 2026

Wilcrest Pharma Awarded Outsourced Compounded Preparations Agreement with Premier, Inc.

GlobeNewswire

Apr. 17, 2026

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

GlobeNewswire